Inside the FDA: The Business and Politics behind the Drugs We Take and the Food We Eat.(Book review) From: Independent Review | Date: January 1, 2007| Author: Conko, Gregory | COPYRIGHT 2007 Independent Institute. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group.Copyright information

Inside the FDA: The Business and Politics behind the Drugs We Take and the Food We Eat By Fran Hawthorne New York: John Wiley and Sons, 2005. Pp. 338. $27.95 cloth.

In October 1988, one thousand AIDS activists, patients, and supporters marched on the U.S. Food and Drug Administration's (FDA) headquarters in Rockville, Maryland, to protest what they viewed as the agency's apathetic approach to the introduction of new AIDS treatments. As Fran Hawthorne describes the scene ...

Related newspaper, magazine, and journal articles from HighBeam Research

	FDA review may be limiting thyroxine supplies. (New Drug Applications Under Study). OB GYN News ; WASHINGTON -- A Food and Drug Administration ruling may be limiting supplies of thyroxine preparations, according to a fact sheet released by the American Thyroid Association at its annual meeting. In 1997, the FDA decided that a new review was needed to ensure the safety and efficacy of these
	Pfizer and Sanofi-Aventis have filed a new drug application with the FDA for Exubera.(PRODUCT NEWS) Medical Marketing & Media ; Pfizer and Sanofi-Aventis have filed a new drug application with the FDA for Exubera, a dry powder form of insulin that is inhaled into the lungs.
	FDA's Temple engages M.D. on new-drug "Over Doses". (As I see it). Medical Marketing & Media ; One physician says current drug formulations have unnecessarily high recommended dosages. The FDA says start low, go slow may not always be the right approach. FDA director of medical policy for drugs Robert Temple in December took on the author of a new book that criticizes both the agency and the
	FDA Approves Viral Hepatitis Medication; Sales of New Drug May Generate $200 Million Annually for Gilead Sciences The Washington Post ; The Food and Drug Administration last night approved a long- awaited drug for a form of viral hepatitis, expanding treatment options for a disease that afflicts more than 1 million Americans. The action was a significant boost for Gilead Sciences Inc., a Foster City, Calif., biotechnology company
	Assessing the FDA's New Drug-Approval Rules NJBIZ ; Mark Kolb THE NJBIZ INTERVIEW NJBIZ: Why is the Food and Drug Administration [FDA] coming out with these new rules and policies? Kolb: They are trying to speak to this big problem we have-there are just not enough new drugs coming to market. Each year, the industry spends more and more on research

See all results.